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Case scenario 
 
You are seeing a 62 year male patient in your clinic with longstanding lower urinary 
tract symptoms (LUTS) refractory to medical management.  His international prostate 
symptom score (IPSS) is 22/35 and he is very unhappy about his current condition.  A 
digital rectal exam is benign with no appreciable nodules.  Given his overall good 
health and degree of symptoms, you recommend a transurethral resection of the 
prostate (TURP) which you consider the most effective treatment for symptomatic 
benign prostatic hyperplasia (BPH).  The patent is willing to undergo surgery but asks 
about whether he could undergo one of more ‘modern’ minimal invasive treatment 
forms that he has heard good things about.  You decide to update your knowledge by 
searching for the current best evidence on the surgical treatment of BPH.   
 
Clinical question 
 
In patients with BPH (population), how effective are minimally invasive treatments 
(interventions), when compared with TURP (comparator), in improving symptom 
scores after surgery (outcome)? 
 
Finding the best evidence 
 
You decide to look for a well-designed systematic review on this topic using 
PubMed.1  Two sets of searches using the terms ‘benign prostatic hyperplasia’ and 
‘minimally invasive surgery’ that you combine with the AND function yields 266 
citations (date of search: October 12, 2009).  Using the Limits tub to apply a 
‘systematic review’ filter from ‘Subset/Topic’ limits the search results to 18 review 
articles.  Here, you identify a systematic review entitled ‘Minimally invasive 
treatments for benign prostatic enlargement: systematic review of randomised 
controlled trials’ that addresses your research question.2   
 
In this review, 22 trials met the review inclusion criteria.  Of these, eight trials 
reported data on symptom scores 12 months after surgery (primary outcome).  Of 
these, three trials compared TURP with transurethral microwave treatment (TUMT), 
one with transurethral needle ablation (TUNA) and four with laser coagulation.  You 
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also notice that the review produced a quantitative summary of results across studies 
(a meta-analysis) for each comparison.  The individual trial results and the summary 
result are shown visually in a ‘forest plot’ figure (Figure 1).   
 
Evaluating the methods 
 
Criteria for assessing validity of review articles have been previously described.3  You 
decide to use the PRISMA (Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses) checklist,4 and are satisfied that the methods of the systematic review 
were strong.  Turning to the results, you now assess whether the results are similar 
(consistent) from study to study; in other words, whether there is any heterogeneity 
among studies included in the systematic review.   
 
What is heterogeneity? 
 
In interpreting the results of a meta-analysis, it is important to consider not just the 
summary result but the degree to which the individual studies assess the same clinical 
question and that their results agree.  Where the included patients and application of 
the interventions broadly similar? Are the results consistent (homogeneous) or do they 
vary so much that the summary is not reliable?  Variability in the study results beyond 
that which could be expected by chance is called (statistical) heterogeneity.  To some 
extent, it is inevitable that the estimated effects of a specific intervention will vary 
from study to study since two studies are never identical in design and conduct.5  
However, assessment of heterogeneity is not purely a statistical issue but also 
involves clinical judgement as to whether it is sensible to combine individual studies 
or not.  Such considerations should occur prior to conducting a meta-analysis. 
 
The first step for identifying heterogeneity is to visually inspect the forest plot.  Is the 
direction and magnitude of effect consistent across studies?  Do the confidence 
intervals for individual trials tend to overlap?  A large difference in the point 
estimates with a lack of overlap in confidence intervals would indicate the presence of 
heterogeneity. 
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The second step is to look at a statistical test of homogeneity (i.e. no 
heterogeneity).,The result of such a test is commonly shown in forest plots and it 
formally assesses whether there is evidence of heterogeneity.  A statistically 
significant result from this test (conventionally assessed using a p-value of 0.10 as 
opposed to 0.05 due to low sensitivity) indicates systematic variability in study results 
beyond chance.  Another way of expressing this information is through the I2 statistic 
that quantifies the inconsistency of study estimates. 5,6  The I2 ranges from 0% to 
100% with larger values indicating a greater proportion of variability is attributable to 
heterogeneity.  As a rough guideline, I2 values higher than 50% may indicate a 
moderate to severe heterogeneity that requires caution.6  Such statistical approaches 
are no panacea; they are influenced by the number and size of studies included in the 
meta-analysis and the underlying level of heterogeneity.5,7 The magnitude of 
heterogeneity (τ2 value) could also be considered. When heterogeneity should be 
considered problematic is debatable.   
 
In our example for the outcome of reduction in symptom scores after surgery, of the 
four trials comparing laser coagulation with TURP, three trials have point estimates 
(mean difference) greater than 0 (suggesting TURP is better than laser coagulation), 
whereas the other has point estimates less than 0 (suggesting laser coagulation is 
better; see Figure 1).  Looking at the confidence intervals for the same comparison, 
the intervals are quite diffuse.  The p-value for the χ2 test is less than 0.10 signifying 
statistical evidence of heterogeneity.  The corresponding I2 is over 80% suggesting a 
high level of heterogeneity.  Caution is therefore required in interpreting such results.  
Similarly for the comparison of  TUMT with TURP, the confidence interval of one of 
the studies (de la Rosette) does not overlap with the other two; Again, this is reflected 
in a high I2 value of 84%. 
 
Causes of heterogeneity 
 
We distinguish the potential sources of heterogeneity (clinical and methodological 
differences) from observing (statistical) heterogeneity in the results.  Variation in the 
estimated intervention effects may reflect differences in patient characteristics, the 
study setting, or how the interventions were implemented in the included studies 
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(clinical heterogeneity).  Differences in findings may also result from methodological 
differences (methodological heterogeneity) such as failure to introduce important 
methodological safeguards against bias such as allocation concealment and blinding.   
 
In our example, the review authors postulate that differences in prostate size and 
symptom score at baseline may be important sources of heterogeneity observed when 
looking at the results after surgery.  For laser coagulation, the authors also noted 
variation in operative technique and treatment protocols between trials (e.g. power 
settings, temperature and site or duration of laser application).  They noted that it was 
difficult to assess their possible impact on intervention effects, as many trials did not 
describe the technologies used in sufficient details, a problem regularly encountered 
when conducting systematic reviews.  
 
What can we do when there is heterogeneity? 
 
In the presence of large unexplained heterogeneity investigators may choose not to 
pool the study results and only report the results of the individual studies.  
Investigators may decide to conduct a random effects meta-analysis as was done for 
our example.  Use of a random-effects model does not remove heterogeneity but 
formally allows for a degree of variability between individual trial results (random 
effects) while still assuming overall coherence.  When there is heterogeneity, the 
confidence intervals around the summary (overall) estimate in the random-effects 
analysis will be wider than the corresponding one from a fixed-effect analysis.  Many 
therefore see the random-effects approach as the more conservative (and arguably the 
default) option.8  However, compared to a fixed-effect meta-analysis, smaller studies 
will be given more influence in a random-effects meta-analysis.  Particular care is 
required when trial size varies greatly or there are few studies.  This difference can be 
seen in Figure 2 where the random effects analysis of the same studies is conducted 
and the point estimate and the confidence interval for the summary estimate differ.  
 
Applying the results to the care of your patient 
 
Having applied the outlined methodology to assess the impact of heterogeneity in the 
case study, you take a cautious approach.  Current evidence does not support 
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minimally invasive treatments over TURP in terms of symptoms at 12 months, let 
alone does there appear to be any high quality evidence on the long-term outcomes in 
the published literature.  Indeed, current best available evidence supports TURP over 
TUNA and tends to favour TURP over the other two minimally invasive treatments.  
Given this, you explain to your patient that the evidence suggests TURP to be at least 
as good as minimally invasive treatments and possibly the superior treatment of 
LUTS secondary to BPH in terms of symptom control at 12 months.  You would also 
want to apply the same approach to the other important outcomes reported such as 
peak urine flow, the need for reoperation and possible adverse effects.   
 
Conclusion 
 
Urologists are often faced with systematic reviews of individual clinical trials with 
inconsistent results.  In this case, it is important to assess the extent and magnitude of 
heterogeneity and ask whether investigators have sufficiently explored clinical and 
methodological sources of heterogeneity, which was the focus of a previous BJUI 
article.9  Uncritical interpretation of meta-analysis can be misleading and misguide 
clinical practice.  The ability to recognize and interpret heterogeneity is therefore 
critical to evidence-based practice of urology.   
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